PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Dentis posted large losses in 2025 but returned to profit for two straight quarters in early 2026, even as its debt ratio and earnings volatility remain elevated.
The 2025 annual operating loss widened sharply and owners' net income turned negative, but both Q1 and Q2 2026 returned to profit.
The debt ratio rose from 269.8% in 2024 to 356.6% in 2025, as equity erosion from the net loss increased leverage.
Implants accounted for 81% of 2024 revenue, while the company diversifies into operating-room solutions (LUVIS) and clear aligners (Ceraphin).
Overseas subsidiaries in eight countries including the US, China, India and Europe, backed by FDA, CE and NMPA approvals, are expanding the global supply network.
The company maintains a no-dividend policy, and shares trade at a discount to net asset value.
Founded in 2005 as a dental implant maker, Dentis has since expanded into surgical solutions, biomaterials, digital dentistry and dental equipment.
Based on 2024 results, product revenue mix was implants 81%, medical lighting 16%, dental 3D printers 1%, and bio materials (synthetic bone and grafts) 3%, with exports and domestic sales at 54.5% and 45.5% respectively, meaning more than half of sales come from overseas.
Implants are run on two premium lines, SQ Implant and AXEL, and AXEL has completed European CE certification and US FDA approval, with expanded sales expected in Europe, the US, China and India.
SQ Implant has obtained approval from China's National Medical Products Administration (NMPA), building a direct-supply structure centered on the China subsidiary.
The medical device division has expanded its surgical lighting brand LUVIS into a total operating-room solution brand that includes surgical tables and unit chairs, and it holds the number-one market share in Korea's surgical lighting market.
LUVIS products have obtained FDA, CE and NMPA certifications and are exported to about 80 countries, with strategic partnerships (Global Team LUVIS) formed with Infinium in the US and Hospedia Medicare in India to expand overseas supply.
The clear aligner brand Ceraphin, run through subsidiary Tienes, is another pillar of business diversification.
The company operates overseas subsidiaries in eight countries including the US, China, Spain, Portugal, Malaysia, India, Vietnam and Thailand, and its competitive landscape overlaps domestically and internationally with listed Korean implant makers such as Osstem Implant, Dentium and Megagen Implant.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩32.4B | -₩300M | −1.0% |
| 2025Q3 | ₩26.6B | -₩1.6B | −5.9% |
| 2025Q4 | ₩22.8B | -₩9.6B | −42.0% |
| 2026Q1 | ₩30.2B | ₩3.1B | 10.1% |
| 2026Q2 | ₩32.1B | ₩2.6B | 8.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩87.1B | ₩5.6B | ₩1.2B | 6.4% | 4.2% | 306.4% |
| 2023 | ₩94.3B | ₩400M | ₩3.8B | 0.5% | 6.9% | 226.8% |
| 2024 | ₩114.3B | -₩400M | ₩2.9B | −0.4% | 5.3% | 269.8% |
| 2025 | ₩114.2B | -₩10.4B | -₩14.2B | −9.1% | −30.6% | 356.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Revenue rose steadily from KRW 87.1 billion in 2022 to KRW 94.3 billion in 2023 and KRW 114.3 billion in 2024, but stayed roughly flat at KRW 114.2 billion in 2025.
Operating profit narrowed from KRW 5.6 billion in 2022 to KRW 0.4 billion in 2023, flipped to a small operating loss of KRW 0.4 billion in 2024, and then widened sharply to a KRW 10.4 billion loss in 2025.
Owners' net income likewise stayed positive at KRW 1.2 billion, KRW 3.8 billion and KRW 2.9 billion in 2022-2024, before turning to a net loss of KRW 14.2 billion in 2025.
On a quarterly basis, the deterioration was driven by Q3 2025 (operating loss of KRW 1.6 billion, owners' net loss of KRW 0.6 billion) followed by an even sharper Q4 2025, when the operating loss widened to KRW 9.6 billion and owners' net loss to KRW 8.1 billion.
However, the company returned to profit in Q1 2026 with operating profit of KRW 3.1 billion and owners' net income of KRW 6.4 billion, and continued this in Q2 2026 with operating profit of KRW 2.6 billion and owners' net income of KRW 3.8 billion, marking two consecutive profitable quarters.
Over this period, the operating margin improved from -9.1% in 2025 to about 10.1% in Q1 2026 and 8.2% in Q2 2026, approaching double-digit profitability.
Operating cash flow (CFO) turned into three consecutive years of net outflow in 2023-2025 (-KRW 9.4 billion, -KRW 5.4 billion, -KRW 9.7 billion) after a KRW 5.2 billion inflow in 2022, indicating cash generation has not yet fully recovered alongside the earnings improvement.
The debt ratio fluctuated from 306% in 2022 to 227% in 2023 and 270% in 2024, then rose to 357% in 2025, as equity erosion from the net loss increased leverage.
Korea's implant industry has grown on the back of expanded national health insurance coverage and rising procedure demand tied to an aging population, and political circles have recently discussed lowering the insurance-eligible age for implants, though this remains at the policy-discussion stage with no confirmed implementation timeline.
China's Volume-Based Procurement (VBP) policy is expected to lower implant material costs and procedure fees to expand adoption structurally, though a competitor, Dentium, saw delays in VBP 2.0 implementation lead to slower orders, showing that timing volatility around policy rollout persists.
India's medical device market is projected to grow from $15.3 billion in 2023 to $20.5 billion by 2029 at roughly 5% annually, and India's dental devices market itself is forecast to grow from $1.8 billion in 2026 to $4.76 billion by 2035, marking it as a high-growth region.
In the competitive landscape, Korea's large players Osstem Implant and Dentium compete alongside Megagen Implant, while Shinhung is pursuing more than a tenfold increase in production capacity after obtaining Chinese approval for its self-developed implant 'evertis', intensifying competition further.
The global operating-room equipment market is projected to reach $5.7 billion by 2027 according to iData Research, with North America, Asia-Pacific and Western Europe—Dentis's target regions—accounting for 45%, 21% and 19% respectively.
The company stated "if 2025 was a period of laying the groundwork for future growth, 2026 will be the year those results become fully visible", setting a goal of securing both profitability and growth by strengthening its core business.
According to the company, the India subsidiary has continued double-digit revenue growth, the Portugal subsidiary has expanded growth centered on the European market, and the Thailand and Vietnam subsidiaries established last year have begun generating meaningful sales.
In June, the company participated in Sino-Dental 2026 in Beijing, showcasing the NMPA-approved SQ Implant and SQ GUIDE system along with new products tailored to local demand, continuing its push into the China market.
In May, the full lineup of the LUVIS Chair dental unit chair and the portable intraosseous anesthesia device DENOPS-i obtained CE MDR certification, laying the groundwork for expanded supply to large European clinics and dental service organizations (DSOs).
For its operating-room solutions, the company has stated it is targeting $11.25 million in surgical solution revenue over the three years from 2025 to 2027 based on partnerships with Infinium in the US and Hospedia Medicare in India.
At the KIMES 2026 exhibition in March, the company unveiled an integrated OR solution combining surgical lights and tables, stating a goal of leveraging its number-one domestic surgical lighting position to advance toward becoming a global top-5 brand.
Because Dentis posted a full-year net loss in 2025, it passed through a period where traditional earnings-based valuation metrics were difficult to apply. With two consecutive profitable quarters in the first half of 2026, the basis for earnings-based valuation is starting to re-form.
Shares trade at a level discounted to the company's net asset value, which can be read as reflecting market caution over past earnings weakness and rising financial leverage.
As the company pays no dividend, the future valuation axis is likely to hinge less on dividend yield and more on whether the earnings recovery persists and the balance sheet improves.
Compared with past trading ranges, the current level sits closer to the lower end, suggesting the market is weighing both the 2025 earnings deterioration and the recovery signals from the first half of 2026 simultaneously.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Operating profit and owners' net income turned positive for two consecutive quarters in Q1 and Q2 2026, with operating margin improving to a level close to double digits. This rebound is attributed mainly to production internalization following new plant operations and improvements in cost and SG&A structure. Whether this trend continues into subsequent quarters will require further confirmation from upcoming results.
The premium implant AXEL has obtained European CE certification and US FDA approval, and SQ Implant has obtained NMPA approval in China, and the company is broadening its operational footprint in India, China and Europe through subsidiaries in eight countries. The India subsidiary has continued double-digit revenue growth, according to the company.
The LUVIS brand, once centered on surgical lighting, has expanded into a total operating-room solution including surgical tables and unit chairs, and the company is pursuing joint sales strategies with partners in the US and India.
In Europe, CE MDR certification has laid the groundwork for expanded supply to large clinics and DSOs. This can be viewed as a structural attempt to reduce dependence on the implant business alone.
The full-year 2025 operating loss widened sharply from the prior year, and owners' net income also turned negative. In particular, the loss recorded in Q4 alone accounted for most of the full-year loss, showing volatility where results swung sharply at a specific point in time. This quarterly divergence lowers the predictability of results.
The debt ratio rose from 269.8% in 2024 to 356.6% in 2025, and operating cash flow recorded net outflows for three consecutive years from 2023 to 2025. The combination of equity erosion from the net loss and continued capital expenditure has increased financial burden. If the return to profit does not continue, concerns over leverage management could resurface.
China's VBP policy can structurally expand procedure adoption, but delays in implementation timing can instead slow order flow, as shown by a competitor's case. Domestically, competition continues from large players such as Osstem Implant and Dentium, as well as Shinhung's new implant 'evertis'.
Institutional changes such as adjusting the insurance-eligible age for implants in Korea remain at the discussion stage, with implementation and timing uncertain.
Sales and order flow could fluctuate in the short term depending on VBP policy implementation timing and detailed conditions, as evidenced by a competitor's delay in VBP 2.0 rollout. As the share of China revenue grows, sensitivity to such policy variables could increase correspondingly.
A debt ratio of 356.6% and three consecutive years of net operating cash outflow could burden the funding needed for continued capital expenditure and overseas subsidiary expansion. If net losses recur, further equity erosion could push leverage even higher.
If a pattern of large losses concentrated in a single quarter, as seen in Q4 2025, recurs, the predictability and reliability of annual results could decline. This also adds uncertainty to future earnings guidance and investment planning.
Q3 2026 results are expected to be disclosed - it will be important to confirm whether the H1 profit trend and near-double-digit operating margin continue into Q3.
Progress on SQ Implant sales expansion in China under NMPA approval, and any changes in VBP-related policy, should be monitored.
Whether supply expansion to large clinics and DSOs based on the European CE MDR certification becomes visible in results should be checked.
Whether the debt ratio and operating cash flow show signs of improvement, easing the leverage burden that built up in 2025, should be checked.
Dentis went through a difficult year in 2025, recording a full-year operating loss and net loss, but showed signs of a rebound by returning to profit for two consecutive quarters in Q1 and Q2 2026.
After steady revenue growth from 2022 to 2024 and a plateau in 2025, the company is seeking to resume growth through overseas subsidiary expansion and international certifications, centered on its implant and OR-solution businesses.
However, the debt ratio rising to 356.6% and three consecutive years of net operating cash outflow remain financial burdens. External variables such as China's VBP policy, domestic health insurance policy discussions, and the pace of expansion in European and Indian markets could also affect future results.
Overall, this is a phase where the sustainability of the return to profit and improvement in leverage need to be confirmed together through upcoming earnings releases and financial metric trends in the second half of 2026 and beyond.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.